BioSpace News Archive

Arcutis Biotherapeutics, Inc. today announced that the INTEGUMENT-PED pivotal Phase 3 trial of roflumilast cream 0.05%, in children ages 2 to 5 years with mild to moderate atopic dermatitis (AD) met its primary endpoint and all secondary endpoints.

Rhythm Pharmaceuticals, Inc. today announced that the European Medicines Agency (EMA) has issued a positive opinion on the Company’s orphan drug designation request for setmelanotide as a treatment for acquired hypothalamic obesity,

Eloxx Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock.

Erasca, Inc. today announced that management will participate in a fireside chat on Tuesday, September 26, 2023, at 8:10 am Eastern Time at the Cantor Global Healthcare Conference, which is being held at the InterContinental New York Barclay in New York, New York.

Dyadic International, Inc today announced that it entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus™.

Ganymede Bio, the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries, and Kytopen, a leader in the development and commercialization of non-viral transfection tools for genome engineering, today announced a partnership to bring the power of cloud native, structured data to Kytopen’s Flowfect® platforms.

Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO ® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors.

Lineage Cell Therapeutics, Inc. announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the Cantor Fitzgerald 2023 Global Healthcare Conference, in a fireside chat hosted by Kristen Kluska.

BioLoomics , the company pioneering directed evolution of target degrading antibodies using human cells, today announced it has raised $8.7 million in seed financing to advance its proprietary platform technology and antibody degrader programs.

AuraVax Therapeutics, Inc. today announced that their partners at the University of Houston presented data at Keystone Symposia: Vaccinology During and After COVID-19 taking place from September 17-20, 2023.